Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H013
UPID:
ADA19_HUMAN
Alternative names:
Meltrin-beta; Metalloprotease and disintegrin dendritic antigen marker
Alternative UPACC:
Q9H013; Q9BZL5; Q9UHP2
Background:
Disintegrin and metalloproteinase domain-containing protein 19, also known as Meltrin-beta, plays a crucial role in neurogenesis and synaptogenesis through the proteolytic processing of beta-type neuregulin isoforms. Its activity extends to the cleavage of alpha-2 macroglobulin and potentially influences osteoblast differentiation and activity in bone.
Therapeutic significance:
Understanding the role of Disintegrin and metalloproteinase domain-containing protein 19 could open doors to potential therapeutic strategies.